




8 May 2020

Your Reference: AA1000486

Mr Simon Bell, ACCC

By Email: 

Dear Mr Saunders and Mr Bell

MEDICINES AUSTRALIA APPLICATION FOR AUTHORISATION AA1000486 – ACCC REQUEST FOR INFORMATION

We write in response to your letter of 29 April 2020 and welcome the opportunity to provide feedback on this important matter.

Gilead Sciences Pty Ltd (**Gilead**) has not yet needed to make use of the interim authorisation and therefore is unable to comment on whether the approach is working as expected. To date, we also do not have any concerns about the practical operation of the ACCC's interim authorisation.

However we support the industry principles set out in the ACCC interim authorisation and the decisive action of the ACCC in taking the decision. We strongly believe the ACCC interim authorisation was an important measure necessary to ensure that the pharmaceutical industry was in the right position to collaboratively and appropriately support the scientific and unmet supply needs in the context of the COVID-19 pandemic in Australia.

We also confirm we have no objection to this response being included the public register, subject to the usual redaction for personal data.

Yours sincerely



Lena Moran-Adams
*Head of Legal and Business Conduct
Australia and New Zealand*